Adaptimmune Therapeutics Retained Earnings (Accumulated Deficit) 2015-2024 | ADAP

Adaptimmune Therapeutics retained earnings (accumulated deficit) from 2015 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Adaptimmune Therapeutics Retained Earnings (Accumulated Deficit) 2015-2024 | ADAP

Adaptimmune Therapeutics retained earnings (accumulated deficit) from 2015 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B